Owing to their small molecular weight, good lipid-to-water ratio, and strong BBB permeability, TKIs have greatly contributed to the progress of treatment of patients with EGFR-positive NSCLC CNS metastasis; however, driver mutations often mean an increase in the incidence of BMs [8,9]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.